Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C
Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C
Efficacy and safety is compared between interferon alfacon-1 alone and concomitant dosing of
 interferon alfacon-1 and ribavirin in hepatitis C patients.
Inclusion Criteria:

 -  Hepatitis C patients (high titer, genotype1)

 Exclusion Criteria:

 -  Patients with autoimmune disorder

 -  Patients with negative HBs antigen

 -  Patients with hepatic cirrhosis, hepatic failure and hepatic cancer

 -  Patients with depression or psychoneurotic disorder